---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-034907"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:50:20.078535+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MetaVia reports FY2025 net loss $13.0M; DA-1726 Phase 1 shows 9.1% weight loss

## Summary
- Net loss of $13.0M ($7.35/share) vs $27.6M ($39.13/share) in FY2024; revenue not reported.
- Cash and cash equivalents $10.3M at Dec 31, 2025; with Jan 2026 $9.3M offering, funds operations into Q4 2026.
- DA-1726 48 mg Phase 1 data: 9.1% weight loss, reduced waist circumference, improved glucose and liver stiffness.
- Phase 1 Part 3 titration study (48 mg and 64 mg) IRB approved; dosing starts April 2026, data expected Q4 2026.
- Vanoglipel Phase 2a MASH data presented at AASLD; end-of-Phase 2 FDA meeting being scheduled.

## SEC filing metadata
- accession: 0001104659-26-034907
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000110465926034907/0001104659-26-034907-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000110465926034907/mtva-20260326x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-034907
- JSON: https://secwatch.observer/filing/0001104659-26-034907.json
- Plain text: https://secwatch.observer/filing/0001104659-26-034907.txt

## Key facts
- Earnings Releases
  MetaVia Inc. reported financial results for the year ended December 31, 2025.
  - Period: the year ended December 31, 2025
  - Result: reported results
  source text: On March 26, 2026, MetaVia Inc. issued a press release announcing its financial results for the year ended December 31, 2025 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638287/000110465926034907/0001104659-26-034907-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.